FDA Approves Posluma

FDA Approves Posluma (flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer MONROE TOWNSHIP, N.J. & OXFORD, England–(BUSINESS WIRE) May 30, 2023 –Blue Earth Diagnostics, a […]

Read more

FDA Approves Yuflyma

FDA Approves Yuflyma (adalimumab-aaty), a Biosimilar to Humira JERSEY CITY, N.J.–(BUSINESS WIRE) May 24, 2023 –Celltrion USA today announced that the U.S. Food and Drug Administration (FDA) has approved Yuflyma® […]

Read more

FDA Approves Brixadi

FDA Approves Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder Plymouth Meeting, Pa. — May 23, 2023—Braeburn announces that the U.S. Food and Drug Administration (FDA) […]

Read more

FDA Approves Skinvive by Juvéderm

FDA Approves Skinvive by Juvéderm (hyaluronic acid) Microdroplet Injection to Improve Skin Smoothness of the Cheeks IRVINE, Calif., May 15, 2023 /PRNewswire/ — Today, Allergan Aesthetics, an AbbVie company (NYSE: […]

Read more

FDA Approves Uzedy

FDA Approves Uzedy (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults PARSIPPANY, N.J., TEL AVIV & PARIS, April 28, 2023 – Teva Pharmaceuticals, a U.S. affiliate of […]

Read more
1 2 3 14